The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 53, Issue 4, 2016, Pages 1523-1538

  De Vos, Ann ^a   Struyfs, Hanne ^b   Jacobs, DIrk ^a   Fransen, Erik ^c   Klewansky, Tom ^d   De Roeck, Ellen ^b,e   Robberecht, Caroline ^b,f   Van Broeckhoven, Christine ^b,f   Duyckaerts, Charles ^d   Engelborghs, Sebastiaan ^b,g   Vanmechelen, Eugeen ^a  

^a ADX NEUROSCIENCES   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^g Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

Author keywords

Alzheimer's disease; BACE1 protein; Biomarkers; Cerebrospinal fluid; ELISA; Mild cognitive impairment; Neurogranin; Prognostic; Ratio

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; NEUROGRANIN; TAU PROTEIN; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; SECRETASE;

AGE; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COMPLICATION; MENTAL HEALTH; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; AREA UNDER CURVE; ASPARTIC ACID ENDOPEPTIDASES; COGNITIVE DYSFUNCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; NEUROGRANIN; TAU PROTEINS;

EID: 84981725399     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160227     Document Type: Article

References (51)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
3. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
4. Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D, Blankenstein MA, Scheltens P, van der Flier WM (2014) The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean? Alzheimers Dement 10, 713-723.
5. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: Validation of two novel assays. J Alzheimers Dis 43, 183-191.
6. Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C (2014) Additional use of A42/A40 ratio with cerebrospinal fluid biomarkers P-tau and A42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J Alzheimers Dis 41, 377-386.
7. Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W, Kaye J, Manczak M (2005) Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction. J Alzheimers Dis 7, 103-117; discussion 173-180.
8. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
9. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
10. Díez-Guerra FJ (2010) Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 62, 597-606.
11. Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J (1990) Neurogranin: Immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci 10, 3782-3792.
12. Watson JB, Sutcliffe JG, Fisher RS (1992) Localization of the protein kinase C phosphorylation/calmodulin-binding substrate RC3 in dendritic spines of neostriatal neurons. Proc Natl Acad Sci U S A 89, 8581-8585.
13. Zhong L, Cherry T, Bies CE, Florence MA, Gerges NZ (2009) Neurogranin enhances synaptic strength through its interaction with calmodulin. EMBO J 28, 3027-3039.
14. Baudier J, Deloulme JC, Van Dorsselaer A, Black D, Matthes HW (1991) Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem 266, 229-237.
15. Sjöstedt E, Fagerberg L, Hallström BM, Häggmark A, Mitsios N, Nilsson P, Pontén F, Hökfelt T, Uhlén M, Mulder J (2015) Defining the human brain proteome using transcriptomics and antibody-based profiling with a focus on the cerebral cortex. PLoS One 10, e0130028.
16. KvartsbergH, Duits FH, IngelssonM, AndreasenN, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 11, 1180-1190.
17. De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, Andreasson U, De Surgeloose D, Hernalsteen D, Sleegers K, Robberecht C, Van Broeckhoven C, Zetterberg H, Blennow K, Engelborghs S, Vanmechelen E (2015) C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimers Dement 11, 1461-1469.
18. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O (2015) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. Ann Clin Transl Neurol 3, 12-20.
19. Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 72, 1275-1280.
20. Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res 1362, 13-22.
21. Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K (2015) Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer's disease. Brain 138(Pt 11), 3373-3385.
22. Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P (2015) Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimers Res Ther 7, 40.
23. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37, 925-937.
24. Kandalepas PC, Sadleir KR, EimerWA, Zhao J, Nicholson DA, Vassar R (2013) The Alzheimer's-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol 126, 329-352.
25. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
26. Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP (2010) BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem 112, 1045-1053.
27. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59, 1381-1389.
28. Barao S, Zhou L, Adamczuk K, Vanhoutvin T, van Leuven F, Demedts D, Vijverman AC, Bossuyt X, Vandenberghe R, De Strooper B (2013) BACE1levels correlate with phosphotau levels in human cerebrospinal fluid. Curr Alzheimer Res 10, 671-678.
29. Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, Suárez-Calvet M, Lladó A, Barrera-Ocampo AA, Sepulveda-Falla D, Blesa R, Molinuevo JL, Clarimón J, Ferrer I, Gelpi E, Lleó A (2013) Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol 125, 201-213.
30. Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H (2012) Cerebrospinal fluid profiles of amyloid-related biomarkers in Alzheimer's disease. Neuromolecular Med 14, 65-73.
31. Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ (2015) Soluble BACE-1 activity and sAPP concentrations in Alzheimer's disease and age-matched healthy control cerebrospinal fluid from the Alzheimer's Disease Neuroimaging Initiative-1 baseline cohort. J Alzheimers Dis 46, 431-440.
32. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65, 1102-1107.
33. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y (2007) Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64, 718-726.
34. Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R (2010) BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 20, 253-260.
35. Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Marïen P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014) Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: A longitudinal study. J Alzheimers Dis 42, 1239-1250.
36. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on Aging, Alzheimer's, Association (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease:Apractical approach. Acta Neuropathol 123, 1-11.
37. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
38. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800.
39. Janelidze S, ZetterbergH, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, vanWesten D, Stomrud E, Minthon L, Blennow K, for the Swedish BioFINDER, study group, Oskar, Hansson (2016) CSF A42/A40 and A42/A38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3, 154-165.
40. Wayne PA (2000) Clinical and Laboratory Standards Institute. How to define and determine reference intervals in the clinical laboratory: Approved guideline. CLSI Document C28-A2.
41. Teunissen C, Menge T, Altintas A, Alvarez-Cermenõ JC, Bertolotto A, Berven FS, Brundin L, Comabella M, Degn M, Deisenhammer F, Fazekas F, Franciotta D, Frederiksen JL, Galimberti D, Gnanapavan S, Hegen H, Hemmer B, Hintzen R, Hughes S, Iacobaeus E, Kroksveen AC, Kuhle J, Richert J, Tumani H, Villar LM, Drulovic J, Dujmovic I, Khalil M, Bartos A (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 19, 1802-1809.
42. Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S (2013) Cerebrospinal fluid A1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36, 759-767.
43. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Dominantly Inherited Alzheimer, Network (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
44. Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, BlennowK, Olsson M, Hansson O, Alzheimer's Disease Neuroimaging Initiative, Swedish BioFINDER Study Group (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240-1249.
45. Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L, Hansson O, Wallin A, Zetterberg H, BlennowK, Öhrfelt A (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener 9, 53.
46. Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24, 1023-1027.
47. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P (1996) Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm (Vienna) 103, 603-618.
48. Pannee J, Gobom J, Shaw LM, Korecka M, Chambers EE, Lame M, Jenkins R, MylottW, CarrilloMC, Zegers I, Zetterberg H, Blennow K, Portelius E (2016) Round robin test on quantification of amyloid-1-42 in cerebrospinal fluid by mass spectrometry. Alzheimers Dement 12, 55-59.
49. Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, UmekRM, Vanmechelen E, Vanderstichele H, Stoops E, Lewis J, Vandijck M, KostanjeveckiV, Jeromin A, Salamone SJ, Schmidt O, Matzen A, Madin K, Eichenlaub U, Bittner T, Shaw LM, Zegers I, Zetterberg H, Blennow K (2016) Assessing the commutability of reference material formats for the harmonization of amyloid beta measurements. Clin Chem Lab Med 54, 1177-1191.
50. Zhabotinsky AM, Camp RN, Epstein IR, Lisman JE (2006) Role of the neurogranin concentrated in spines in the induction of long-term potentiation. J Neurosci 26, 7337-7347.
51. Alvarez-Bolado G, Rodríguez-Sánchez P, Tejero-Díez P, Fairén A, Díez-Guerra FJ (1996) Neurogranin in the development of the rat telencephalon. Neuroscience 73, 565-580.